Clinical trials: Huntington's Disease
Huntington Disease
Bioavailability of Ubiquinol in Huntington Disease
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals.
- Trial name
- NCT00980694
- Testing
- ubiquinol
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Rochester
Huntington Disease
Riluzole in Huntington's Disease
Primary objective: The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating…
- Trial name
- NCT00277602
- Testing
- Riluzole
- Volunteers
- 537 people
- Sponsor
- Sanofi
Huntington Disease
Effect of Tetrabenazine on Stroop Interference in HD
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing.
- Trial name
- NCT01834911
- Testing
- Tetrabenazine withdrawal
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Huntington Disease
Longitudinal Endpoint Assessment of Disease Burden in HD
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
- Trial name
- LEAD-HD (NCT06475898)
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Huntington Study Group
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease
This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon…
- Trial name
- NCT05243017
- Testing
- intra-striatal rAAV5-miHTT
- Where
- 4 sites in Poland, United Kingdom
- Volunteers
- 14 people
- Sponsor
- UniQure Biopharma B.V.
Huntington Disease
MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease
The aim of this study is to assess the clinical benefit of intrastriatal grafting of human cells from the foetal ganglionic eminence in patients with Huntington's disease. The duration of the study will be 52 months.
- Trial name
- MIG-HD (NCT00190450)
- Testing
- graft intracerebral of foetal neurons
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease, Huntington's Dementia
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease.
- Conditions
- Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
- Trial name
- SAN-09611 (NCT05773196)
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sanguine Biosciences
HDL
Oral Nutritional Supplement Effect on HDL Function
Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)
- Trial name
- NCT04529174
- Testing
- CardioLux™HDL
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Huntington Disease
Long Term Follow-up Grafted Huntington's Disease Patients
Long-term follow-up of Huntington's disease patients treated with intrastriatal allografts is essential to assess the benefit/risk ratio of grafts as well as their effectiveness.
- Trial name
- Post-MIGHD (NCT06194006)
- Testing
- Follow-up
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease, Juvenile
REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN)
The study aims to monitor the progression of symptoms and signs of those affected by JHD using modified UHDRS scales of motor and function (functional assessment, TFC).
- Trial name
- JHD (NCT01590602)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 78 people
- Sponsor
- European Huntington's Disease Network
Huntington's Disease
A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)
The purpose of this research study is to see if tetrabenazine, which is commonly used to treat Huntington's Disease (HD), reduces the problems of impulsivity that are common in patients with HD.
- Trial name
- NCT02509793
- Testing
- Tetrabenazine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- William Ondo, MD
Huntington's Disease
Study of Memantine to Treat Huntington's Disease
To determine if memantine in doses of 10 mg BID affects memory, cognition, and behavior in patients with Huntington's disease (HD).
- Trial name
- NCT00652457
- Testing
- Memantine
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jody Corey-Bloom, MD, PhD
Huntington's Disease
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase 1/2, multicenter, first-in-human (FIH) study.
- Trial name
- NCT04120493
- Testing
- intra-striatal rAAV5-miHTT
- Where
- 12 sites in United States
- Volunteers
- 43 people
- Sponsor
- UniQure Biopharma B.V.
Huntington Disease
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
The principal means of measuring motor impairment in Huntington disease (HD) is the Unified Huntington's Disease Rating Scale (UHDRS) total motor score, which is subjective, categorical, requires significant training to…
- Trial name
- NCT03599076
- Testing
- HD Wear
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BioSensics
Huntington Disease
FuRST 2.0 Cognitive Pre-testing - Round 2
The study is a single, cross-sectional cognitive interview of FuRST 2.0, functional rating scale, administered to forty Huntington's Disease Gene Expansion Carriers (HDGECs) and potentially, their companions (the companion's…
- Trial name
- NCT03709173
- Testing
- FuRST 2.0
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- CHDI Foundation, Inc.
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
- Trial name
- NCT00931073
- Testing
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington Disease
Project AWARE 2.0 to Improve Awareness, Willingness and Ability for Research and Enrollment in Clinical Research
The Project AWARE 2.0 Survey is intended to gain knowledge about the feelings, attitudes, and beliefs of HD family members, care partners and others affected by HD towards the way drug trials and observational studies are…
- Trial name
- NCT06343220
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Huntington Study Group
Huntington's Disease
Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging
Huntington's disease is a rare genetic neurodegenerative disease. It is accompanied by movement disorders, cognitive and behavioral. The social behavior of patients are changed, affecting interpersonal relationships.
- Trial name
- COSIMH (NCT02550275)
- Testing
- neuropsychological test, MRI
- Where
- France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Huntington Disease
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
- Trial name
- NCT06826612
- Testing
- SPK-10001
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Hoffmann-La Roche